Precigen, Inc. (PGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precigen, Inc. on August 13, 2025. The filing discloses the entry into a Material Definitive Agreement regarding the commercial manufacturing of the Company's product, PAPIZEMOS.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of a new contractual agreement.
Material Changes and Agreement Details
On August 13, 2025, Precigen entered into a Commercial Supply Agreement with Catalent Maryland, Inc. Key terms include:
- Scope of Services: Catalent will provide analytical, development, processing, validation, and product maintenance services for PAPIZEMOS.
- Exclusivity: Precigen has agreed to use Catalent exclusively for external, commercial fill and finish manufacturing of all reported volumes of the product within the defined territory.
- Minimum Commitments: The Company is obligated to purchase a minimum number of batches if specified in the Plan Document for any contract year.
- Pricing: Fees are subject to annual adjustments to reflect increases in labor, utilities, and overhead.
- Term: The initial term is three years, with automatic one-year extensions unless terminated with at least twelve months' notice.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future performance. The agreement includes standard provisions for termination due to material breach and customary clauses regarding quality, intellectual property, and indemnification. Portions of the agreement containing confidential pricing or volume details were omitted from the public filing.
Investor Verification Checklist
- Review the full text of the Commercial Supply Agreement (Exhibit 10.1) for specific pricing structures and minimum batch requirements.
- Verify the definition of the "Territory" and "Plan Document" referenced in the agreement to understand the scope of exclusivity.
- Monitor future filings for any updates on the commercial launch timeline of PAPIZEMOS.
- Check for any subsequent 8-K filings regarding amendments to the agreement or changes in manufacturing partners.